ESMA updated its manual on post-trade transparency under MiFID II and MiFIR on 15 October 2026, adding guidance on identifying OTC derivatives subject to transparency requirements and on applying the tick-size regime. The document reference is ESMA74-2134169708-6870.

The update targets two persistent pain points for desks: which OTC derivatives fall under transparency obligations, and when trading venues and national competent authorities (NCAs) can intervene on tick size. ESMA frames the revision as a supervisory convergence exercise — aligning how NCAs across member states apply rules that already exist, not creating new obligations.

For reporting teams, the practical change sits in the reference-data section. The manual now clarifies how identifying reference data for OTC derivatives should be provided for transparency purposes. ESMA says the goal is greater consistency in the data reported to, and published through, the consolidated tape.

What does the update actually contain?

Three components:

• OTC identification guidance — further direction on which OTC derivatives are subject to transparency requirements.
• OTC reference-data clarification — how identifying reference data should be supplied for transparency purposes, to support consistent consolidated tape input.
• Tick-size regime material — several published Q&As on tick size, plus new recommendations on application, including when trading venues and NCAs may intervene in specific circumstances.

The tick-size additions matter for venue operators and compliance teams. Recommendations on when intervention is permitted give venues and supervisors a common reference point. That narrows the room for divergent national practice — the divergence that motivates convergence manuals in the first place.

Which parts are final and which are draft?

Here the timeline matters, and desks should read it carefully.

The tick-size guidance and Q&As are published recommendations. They carry supervisory-convergence weight from ESMA but sit below the level of binding technical standards.

The OTC identifying-reference-data guidance is explicitly provisional. ESMA states the updated manual "should be considered a draft until the entry into force of the related technical standards" — specifically RTS 2 and the RTS on CTP input/output data.

That drafting status has a workflow consequence. Firms building or maintaining OTC derivative reporting pipelines against this guidance are aligning to a moving target: the binding specifications arrive with the RTS, not with this manual. Technology teams should treat the current text as directional, not contractual, when mapping reference-data fields.

What it changes for execution and reporting desks

The consolidated tape angle is the one to watch. ESMA ties the OTC reference-data clarification directly to "greater consistency in the data reported to and published through the consolidated tape." Cleaner identifying reference data means fewer reconciliation breaks between what firms report and what the tape publishes.

For sell-side reporting infrastructure, the manual's clarifications feed into CTP input specifications that the pending RTS will lock down. For buy-side post-trade monitoring, more consistent OTC derivative identification improves the comparability of published post-trade data.

The tick-size recommendations cut closer to execution. Guidance on when venues and NCAs may intervene addresses the operational question of when a tick-size deviation is sanctioned — relevant to venues managing illiquid instruments and to firms assessing venue behavior during stressed conditions.

Next steps

ESMA has set no compliance deadline in this update; it is guidance, not a rule with an effective date. The binding milestones arrive with RTS 2 and the CTP input/output data RTS, whose entry into force will convert the draft OTC reference-data guidance into settled expectation for reporting chains across the EU.

By Daniel Okafor